文献速递淋巴瘤白血病

高通量药物筛选揭示T细胞幼淋巴细胞白血病对IAP的依赖性

IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening.
PubMed 文献 · Blood · 2025-01-01

该研究对30例原发T-PLL患者样本进行体外高通量药物敏感性筛查,筛选超过2800种化合物,发现T-PLL对多数药物类别(包括化疗药)较其他血液肿瘤更耐药,但对靶向自噬(毒胡萝卜素、巴弗洛霉素A1)、核输出(塞利尼索)和凋亡抑制蛋白(IAP;比瑞纳帕)的药物敏感。比瑞纳帕诱导的细胞死亡主要为坏死性凋亡且依赖TNF-α,对非恶性T细胞影响有限。

要点

  • T-PLL对多数药物类别(含化疗药)较其他血液肿瘤更耐药。
  • T-PLL对自噬、核输出和IAP抑制剂敏感,且与其他T细胞恶性肿瘤共享。
  • IAP抑制剂比瑞纳帕诱导的T-PLL细胞死亡主要为坏死性凋亡且依赖TNF-α。

核心结论

  • 该研究绘制了T-PLL在广泛靶点上的药物敏感性图谱,并确定了靶向IAP、输出蛋白1和自噬的新治疗策略,突出药物重定位的候选药物。

研究设计与样本

  • 对30例原发患者样本进行体外高通量药物敏感性筛查,筛选超过2800种独特化合物。
  • 采用批量和单细胞RNA测序分析化合物激活的信号通路。
  • 采用光谱流式细胞术检测IAP抑制剂处理的T-PLL细胞中cleaved caspase-3。

主要发现

  • T-PLL对大多数药物类别(包括化疗药)较其他血液肿瘤更耐药。
  • T-PLL细胞对靶向自噬(毒胡萝卜素和巴弗洛霉素A1)、核输出(塞利尼索)和IAP(比瑞纳帕)的药物表现出特殊敏感性,且其他T细胞恶性肿瘤也共享这些敏感性。
  • 巴弗洛霉素A1激活Toll样受体、塞利尼索激活p53、比瑞纳帕激活TNF-α/NF-κB信号通路。
  • IAP抑制剂诱导的细胞死亡主要为坏死性凋亡且依赖TNF-α。
  • IAP抑制剂处理的T-PLL细胞中cleaved caspase-3缺失,IAP抑制降低体外刺激的T-PLL细胞增殖,对非恶性T细胞仅显示有限效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell prolymphocytic leukemia (T-PLL) is an aggressive lymphoid malignancy with limited treatment options. To discover new treatment targets for T-PLL, we performed high-throughput drug sensitivity screening on 30 primary patient samples ex vivo. After screening >2800 unique compounds, we found T-PLL to be more resistant to most drug classes, including chemotherapeutics, than other blood cancers. Furthermore, we discovered previously unreported vulnerabilities of T-PLL. T-PLL cells exhibited a particular sensitivity to drugs targeting autophagy (thapsigargin and bafilomycin A1), nuclear export (selinexor), and inhibitor of apoptosis proteins (IAPs; birinapant), sensitivities that were also shared by other T-cell malignancies. Through bulk and single-cell RNA sequencing, we found these compounds to activate the Toll-like receptor (bafilomycin A1), p53 (selinexor), and tumor necrosis factor α (TNF-α)/NF-κB signaling pathways (birinapant) in T-PLL cells. Focusing on birinapant for its potential in drug repurposing, we uncovered that IAP inhibitor-induced cell death was primarily necroptotic and dependent on TNF-α. Through spectral flow cytometry, we confirmed the absence of cleaved caspase-3 in IAP inhibitor-treated T-PLL cells and show that IAP inhibition reduces the proliferation of T-PLL cells stimulated ex vivo, while showing only a limited effect on nonmalignant T-cells. In summary, our study maps the drug sensitivity of T-PLL across a broad range of targets and identifies new therapeutic approaches for T-PLL by targeting IAPs, exportin 1, and autophagy, highlighting potential candidates for drug repurposing and novel treatment strategies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pohly MF, Putzker K, Scheinost S, et al. IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening. Blood. 2025. PMID: 39869826. doi:10.1182/blood.2024027171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。